The prevalence of KRAS and SMAD4 mutations in the Control cell lines was 50% and 17%, respectively, whereas that in cancer type– and sample size–matched clinical tumor populations was 48% and 2.5%, respectively. This evidence concerns the gene KRAS and cancer.